Learn More

Over the course of two years, the Columbia CTD2 Center developed PANACEA (Pancancer Analysis of Chemical Entity Activity), a comprehensive repertoire of dose response curves and molecular profiles representative of cellular responses to drug perturbations. PANACEA covers a broad spectrum of cellular contexts representative of poor outcome malignancies, including rare ones such as GIST sarcoma and gastroenteropancreatic neuroendocrine tumors (GEP-NETs). PANACEA is uniquely suited to support DREAM Challenges related to the elucidation of drug mechanism of action (MOA), drug sensitivity, and drug synergy. The goal of the CTD2 Pancancer Drug Activity DREAM Challenge is to foster the development and benchmarking of algorithms to predict targets of chemotherapeutic compounds from post-treatment transcriptional data.